Similar Search Results

Bargaining and International Reference Pricing in the Pharmaceutical Industry

Dubois, Pierre; Gandhi, Ashvin; Vasserman, Shoshana - National Bureau of Economic Research - 2022

The United States spends twice as much per person on pharmaceuticals as European countries, in large part because prices are much higher in the US. This fact has led policymakers to consider legislation for price controls. This paper assesses the effects of a US international reference pricing...

Persistent link: https://www.econbiz.de/10013210081

Auditing the Prescription Drug Consumer Price Index in a Changing Marketplace

Frank, Richard G.; Hicks, Andrew; Berndt, Ernst R. - National Bureau of Economic Research - 2022

The Bureau of Labor Statistics' Prescription Drug Consumer Price Index (CPI-Rx) has been the focus of considerable controversy in recent years. The CPI-Rx limits its sampling frame to transactions in retail outpatient outlets, and excludes prescription pharmaceuticals dispensed in hospitals,...

Persistent link: https://www.econbiz.de/10013388804

Evaluation and Learning in R&D Investment

Frankel, Alex; Krieger, Joshua L.; Li, Danielle; … - National Bureau of Economic Research - 2023

We examine the role of spillover learning in shaping the value of exploratory versus incremental R&D. Using data from drug development, we show that novel drug candidates generate more knowledge spillovers than incremental ones. Despite being less likely to reach regulatory approval, they are...

Persistent link: https://www.econbiz.de/10014287391

Investigator Racial Diversity and Clinical Trial Participation

Alsan, Marcella; Campbell, Romaine A.; Leister, Lukas; … - National Bureau of Economic Research - 2023

We investigate whether increased racial diversity of clinical trial principal investigators could increase the enrollment of Black patients, which currently lags population and disease-burden shares. We conducted a survey experiment in which respondents were shown a photo of a current NIH...

Persistent link: https://www.econbiz.de/10014372489

Pharmaceutical Innovation, Mortality Reduction, and Economic Growth

Lichtenberg, Frank R. - 1998

We perform an econometric investigation of the contribution of pharmaceutical innovation to mortality reduction and … pharmaceutical innovation, there would have been no increase and perhaps even a small decrease in mean age at death, and that new … drugs have increased life expectancy, and lifetime income, by about 0.75-1.0% per annum. The drug innovation measures are …

Persistent link: https://www.econbiz.de/10012472240

The Effect of Pharmaceutical Utilization and Innovation on Hospitalization and Mortality

Lichtenberg, Frank R. - 1996

This paper presents an econometric analysis of the effect of changes in the quantity and type of pharmaceuticals prescribed by physicians in outpatient visits on rates of hospitalization, surgical procedure, mortality, and related variables. It examines the statistical relationship across...

Persistent link: https://www.econbiz.de/10012473446

Generics and New Goods in Pharmaceutical Price Indexes

Griliches, Zvi - 1993

We examine the issue of new goods and price indexes for the important and tractable case of generic and branded drugs. By treating generics as entirely distinct goods and "linking them in" to indexes with fixed weights, the standard price indexes fail to reflect the substantial welfare gains to...

Persistent link: https://www.econbiz.de/10012474690

Insurance Design and Pharmaceutical Innovation

Agha, Leila - 2020

This paper studies how insurance coverage policies affect incentives for pharmaceutical innovation. In the United …

Persistent link: https://www.econbiz.de/10012481418

Expected Profits and The Scientific Novelty of Innovation

Dranove, David - 2020

Innovation policy involves trading off monopoly output and pricing in the short run in exchange for incentives for …

Persistent link: https://www.econbiz.de/10012481677

Organizing Crisis Innovation : Lessons from World War II

Gross, Daniel P. - 2020

World War II innovation model in other crises. In this essay we describe exactly how it worked. We do so first through a … general overview of how OSRD approached several questions that may confront any crisis innovation effort: priority setting … innovation policy different, how crisis innovation policy approaches may vary, and the limits to generalizing from World War II …

Persistent link: https://www.econbiz.de/10012482128